Abstract
Seven adult patients received human immune globulin intravenously as initial therapy for Guillain-Barré syndrome. Although all patients initially stabilized or improved, five patients deteriorated 1 to 16 days after completion of treatment. In all five patients, clinical worsening included loss of at least one functional grade together with a decreased forced vital capacity. We subsequently treated each patient with a course of plasma exchange, which led to varying degrees of clinical improvement in four. In contrast to previously reported relapse rates for Guillain-Barré syndrome, our experience suggests that clinically significant relapses may occur in patients more often following human immune globulin therapy than after either plasma exchange or no therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 872-875 |
Number of pages | 4 |
Journal | Neurology |
Volume | 43 |
Issue number | 5 |
State | Published - May 1993 |
ASJC Scopus subject areas
- Clinical Neurology